Corcept Therapeutics (CORT) Long-Term Investments (2017 - 2026)

Corcept Therapeutics (CORT) has 10 years of Long-Term Investments data on file, last reported at $177.3 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 28.54% year-over-year to $177.3 million; the trailing twelve-month figure through Mar 2026 stood at $177.3 million (down 28.54% YoY), and the FY2025 full-year result was $160.3 million, down 27.09% from the prior year.
• Long-Term Investments advanced to $177.3 million in Q1 2026, from $160.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $248.0 million in Q1 2025 to a low of $4.9 million in Q3 2022.
• A 5-year average of $97.9 million and a median of $59.6 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments plunged 96.34% in 2022 and surged 1118.0% in 2023, its largest moves.
• Tracing CORT's Long-Term Investments over 5 years: stood at $4.9 million in 2022, then surged by 1055.77% to $57.2 million in 2023, then jumped by 284.48% to $219.8 million in 2024, then decreased by 27.09% to $160.3 million in 2025, then advanced by 10.6% to $177.3 million in 2026.
• Business Quant data shows CORT's Long-Term Investments at $177.3 million in Q1 2026, $160.3 million in Q4 2025, and $102.6 million in Q3 2025.